Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

REVIVE SPINE AND PAIN CENTER

NPI: 1235674912 · MARLTON, NJ 08053 · Pain Medicine (Physical Medicine & Rehabilitation) Physician · NPI assigned 01/04/2017

$1.86M
Total Medicaid Paid
39,655
Total Claims
31,928
Beneficiaries
15
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialNAMMOUR, MIKE (MANAGER)
NPI Enumeration Date01/04/2017

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,886 $175K
2019 2,251 $126K
2020 4,961 $250K
2021 5,378 $280K
2022 8,405 $411K
2023 9,377 $377K
2024 6,397 $242K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 15,377 13,596 $861K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 9,204 6,527 $609K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 10,611 8,291 $233K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,519 1,165 $54K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 1,367 992 $53K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 160 160 $14K
20553 252 224 $10K
95911 63 63 $8K
95886 65 65 $6K
64493 36 36 $5K
64495 36 36 $3K
64494 36 36 $3K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml 720 542 $743.27
80305 116 116 $511.12
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 93 79 $351.82